Clinical Trial Update: Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

View source ↗

Summary

A completed clinical trial evaluating molecular predictors of response to the chemotherapy regimen pemetrexed and carboplatin in malignant pleural mesothelioma.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: MALIGNANT PLEURAL MESOTHELIOMA | Status: COMPLETED